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ABSTRACT 
 Epilepsy affects around 50 million people in the world. Thus, it is imperative that 
new more effective and safe treatments be found. This study was designed to use 
zebrafish to screen potential anti-epileptic natural products. We utilized two scn1Lab null 
zebrafish models (morpholino-injected fish where scn1Lab was transiently knocked 
down and a transgenic scn1Lab -/- fish line). Alternatively, we used AB wildtype fish to 
test compounds in a chemically-induced seizure model. Natural compounds including 
cannabidiol, CBD, and Tapinanthus globiferous, TG, extracts were screened for their 
anti-seizure activity. When scn1Lab -/- fish were treated with CBD (0.075 and 0.3 mg/L) 
from 5 to 7 days post fertilization (dpf), a non-significant reduction of seizure-like 
activity, compared to control, was found. Additional exposures are needed to verify this 
reduction. In wildtype fish where seizures were induced by treatment of 
pentylenetetrazole, TG extracts were tested for anti-epileptic potential from 5 to 6 dpf. 
Our results showed that one extract of TG, AF.1.11.TG.4 (0.2, 1, and 5 mg/L) showed 
some promise in reducing seizure-like activity. We conclude that certain extracts of TG 
show promise as anticonvulsants, and CBD requires further research to verify its 
reduction. The transgenic scn1Lab -/- fish once acquired and raised proved to a better 
model for screening natural products for Dravet-specific seizures than morpholino-based 
approaches.  
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1. INTRODUCTION 
 
1.1 Epilepsy  
Epilepsy, which affects 50 million people worldwide, is a central nervous system 
disorder in which the activity of the brain is abnormal (World Health Organization, 
2018). Abnormal brain activity results in seizures or periods of unusual behavior, 
sensations, and sometimes loss of awareness. In half of the people with epilepsy, there 
are no discernable causes for the condition. In others, epilepsy may be caused by genetic 
factors, head trauma, infectious diseases, and prenatal injuries. Seizure symptoms include 
temporary confusion, staring spells, uncontrollable jerking movements of the arms and 
legs, loss of consciousness, and psychic symptoms such as fear and anxiety (Sourbron, 
2015). Epilepsy is most commonly treated with anti-epileptic drugs (AEDs). Common 
side-effects of these pharmaceuticals include fatigue, dizziness, weight gain, and skin 
rashes. However, many of these medications also have more serious side-effects such as 
speech problems, memory or cognitive problems, depression, loss of coordination, and 
inflammation of certain organs. Over the last decade, advances have been made towards 
the development of new AEDs. This is based on the fact that current, available AEDs do 
not provide optimal therapy for patients with epilepsy (French et al., 2004).  
 
1.2 Dravet Syndrome 
 Dravet Syndrome (DS), also known as severe myoclonic epilepsy of infancy 
(SMEI), is a severe form of epilepsy. It appears during the first year of life with frequent 
febrile seizures. Febrile seizures are fever-related seizures and are rare beyond the age of 
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5 (Dravet Syndrome Information Page, 2011). However, as the condition progresses, 
other forms of seizures usually occur such as myoclonus and status epilepticus. In 15 to 
25 percent of DS cases, a family history of either epilepsy or febrile seizures exists. 
Around 80% of cases are due to a mutation in the SCN1A gene, which belongs to a family 
of genes that provide instructions for making sodium channels. This gene is required for 
the proper function of brain cells. Around 10% of the cases are idiopathic. People with 
Dravet Syndrome may suffer from deterioration of intellectual development around age 
2, lack of coordination, poor development of language, hyperactivity, and difficulty 
relating to others (Escayg et al., 2010). The seizures may be triggered by slight increases 
in temperature, various illnesses, and light. People with DS require constant care; the 
condition greatly impacts the lives of the patients as well as the family’s quality of life. It 
is estimated that 10-20 percent of people with DS pass away before adulthood with most 
deaths occurring before the age of 10 years (National Institutes of Health, 2018). 
Treatment of DS includes combinations of medications due to its resistant nature. 
However, some of the common anticonvulsant medications worsen the seizures in DS 
patients. Therefore, it is important to explore newer more viable drug options in order to 
reduce adverse side effects and occurrence of seizures.  
 
1.3 Scn1Lab gene 
It is estimated 80% of DS cases are due to de novo mutations in the SCN1A gene. 
One of the primary monogenic causes of DS includes mutations in Nav1.1 (SCN1A), a 
voltage gated sodium channel. Specifically, it is the Type I channel (over 9 extist), and 
the mutations are found in the α subunit which is responsible for passing the Na+. Studies 
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reported that the altered sodium channels are mainly expressed in the GABAergic 
(inhibitory) interneurons, leading to impaired inhibitory neurotransmission that would 
explain the seizures (Mayo Clinic, 2018). Voltage gated sodium channels (VGSC) are 
essential for neuronal excitability by initiating and propagating the rising phase of the 
action potential (Frank et al., 2003). Therefore, it seems plausible that mutations in 
VGSCs have a role in epilepsy because those channels play a part in controlling electrical 
excitability. Membrane depolarization activates the VGSC, and this causes the voltage-
dependent conformational change that increases the permeability to sodium ions. This 
step further depolarizes the cell. The channel then closes and the permeability to the 
sodium ions decreases and this causes inactivation. The membrane potential is then 
allowed to return to resting level. The exact mechanisms for how mutations in the SCN1A 
gene cause epilepsy are still being researched. However, by using a morpholino and 
chemical mutagenesis, we can develop model organisms with the unique features of DS; 
this allows for the study of the molecular and behavior basis of this specific disease.  
 
1.4 Zebrafish as a model  
Zebrafish (Danio rerio) are tropical fresh-water fish in the minnow family. 
Originally, these fish were found in rivers, ponds, and puddles in India. Over the past two 
decades, zebrafish have become an increasingly popular option for modeling human 
diseases. Zebrafish provide advantages over other animals including high fecundity, 
quick maturation, and the availability of many transgenic mutant strains. Furthermore, the 
embryos develop outside of the parent organism facilitating microscopic visualization 
throughout early development. It is also estimated that around 84% of genes known to 
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human disease are also expressed in zebrafish (Kundap et al., 2017). These attributes 
make zebrafish a useful model for studying human diseases.  
Specific to studies of epilepsy drug discovery, zebrafish have been shown to be an 
effective model because they exhibit seizure phenotypes (French et al., 2004). Zebrafish 
have homologs for 85% of human epilepsy genes (Hortopan et al., 2010). Larval 
zebrafish respond to convulsant drugs (e.g. pentylenetetrazole and allyglycine) 
(Afrikanova et al., 2013; Leclercq et al., 2015), recapitulate seizures of similar duration, 
frequency and electrical discharges as mammals (Hortopan et al., 2010) and have 
corresponding induced expression of c-fos (Rahn et al., 2014; Buenafe et al., 2013). 
Furthermore, zebrafish genetic mutations in VCSCs (Baraban et al., 2013; Zhang et al., 
2015) and chromodomain helicase DNA binding protein 2 (chd2) (Suls et al., 2013) 
spontaneously develop seizures like their mammalian counterparts while also providing a 
much easier model to screen for idiopathic epilepsy therapies. Zebrafish movement can 
be tracked via the ViewPoint Zebrabox, which enables researchers to analyze behavioral 
aspects of the seizures in zebrafish. In recent studies, zebrafish have been used as a model 
for DS using a scn1a antisense morpholino and scn1Lab -/- approaches. Currently, 
fenfluramine and clemizole have emerged from zebrafish screens as promising forms of 
treatment for this particular form of epilepsy (Baraban et al., 2013).  
Pentylenetetrazole (PTZ) is used in zebrafish to induce generalized epileptic 
seizure-like conditions and to study the mechanisms of seizures. PTZ, a GABA receptor 
agonist, can induce convulsive effects by inhibiting the activity of GABA and GABAA 
receptors (Kundap et al., 2017). Exposure to PTZ induces a concentration-dependent 
response of stereotype behavioral changes such as increase in movement and certain 
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swimming patterns.  The use of PTZ alongside natural products with hypothesized 
antiepileptic activity, allows for comparison of drug response and efficacy.  
 Many zebrafish mutant strains have been propagated following random 
mutagenesis. The transgenic scn1Lab fish line was generated following a chemical 
mutagenesis assay using N-ethyl-N-nitrosourea (ENU). ENU is an alkylating agent (to 
usually thymine) that produces small, random, single nucleotide mutations. The protocol 
entails exposing an adult male zebrafish to water containing ENU. After the mutagenesis, 
a three-generation mutant screen is performed; researchers look for phenotypes that are 
characteristic and can be linked to specific mutations (Figure 1). For example, in scn1Lab 
-/- mutants, the fish show darker pigmentation, lack of a swim bladder, slight curvature of 
the body, and seizures (Mayo Clinic, 2018). It is important to understand the genetic 
basis for a specific phenotype. Therefore, researchers typically carry out genetic mapping 
and positional cloning experiments, which allow researchers to pinpoint the location of 
the associated gene and identify the responsible mutation. 
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1.5 Morpholino 
The use of morpholino oligos allows for the transient knockdown of the SCN1A 
gene by blocking translation at the ribosome. Morpholino oligos are designed to 
specifically bind to selected target sites in order to block access of cell components to 
that specific target site. This property is exploited to block translation.  However, the 
same property can be used to block splicing, block miRNAs or their targets, and block 
ribozyme activity (GeneTools, 2018). Morpholinos do not typically cause degradation of 
their RNA targets. Instead, they work through hindering the biological activity of the 
target RNA until that RNA is degraded naturally. Morpholinos must also be administered 
via microinjection; the morpholino is then incorporated via cell division during 
development. A morpholino differs greatly from a regular nucleic acid. For instance, a 
Figure 1: Overview of ENU mutagenesis screen (Deo, 2008) 
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morpholino oligo has methylenemorpholine rings which replace the ribose or 
deoxyribose sugar moieties and non-ionic phosphorodiamidate linkages replace the 
anionic phosphates of DNA and RNA (Figure 2). A 25-base morpholino oligo strongly 
and specifically binds to its complementary 25-base pair target site in a strand of RNA 
because each morpholine ring positions one of the standard DNA bases (GeneTools, 
2018).  
 There is a great benefit to utilizing morpholinos. Morpholinos combine the 
properties of stability, nuclease-resistance, efficacy, long-term activity, water-solubility, 
low toxicity and specificity (GeneTools, 2018). For instance, morpholino oligo is not 
recognized by enzymes or signaling proteins, which makes it completely stable to 
nucleases, and it does not trigger an immune response (GeneTools, 2018). Through this, 
oligo degradation as well as inflammation and interferon induction is avoided. These 
problems are quite common in other gene knockdown reagents. There are negative 
qualities to morpholinos as well. Although morpholino oligos are more soluble than other 
non-ionic structural types, some morpholinos with high G content (greater than 30%) do 
have limited solubility. Solubility also varies with the oligo sequence and is difficult to 
predict. An important factor to consider when using morpholinos in zebrafish is that it 
produces a transient knockdown; this is due to the fact that the morpholino is diluted as 
the fish develops.  
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1.6 Natural products with hypothesized anti-seizure activity   
Various preparations of natural products in the form of injectable extracts, 
infusions, fluid extracts or tea bags are widely used in different cultures around the world 
to treat various diseases including epilepsy. Tapinanthus globiferus (TG) is a species of 
mistletoe in the Loranthaceae family. This plant is hemiparasitic and is found in parts of 
western Africa. Mistletoe grows on various types of trees such as shea butter tree, the 
cocoa tree, the sweet orange tree, hog-plum tree, and rubber trees. These various trees are 
valuable to the farming community, so TG is seen as a nuisance. That said, TG also has 
been used to treat ailments. Traditionally, the leaves of TG are crushed up, soaked in 
either cold water or beer and then the liquid is orally consumed (Adesina et al, 2013). 
There is not a substantial number of controlled studies which substantiate the 
effectiveness of TG in the treatment of epilepsy. However, TG has traditionally been 
used to treat some forms of epilepsy, and other mistletoes have shown success in treating 
epilepsy (Adesina et al., 2013). For this reason, we are interested in exploring the anti-
seizure properties of TG.  
Following the exploration of TG, we were interested in studying the properties of 
Cannabidiol (CBD). The potential for cannabis as a treatment for seizures is growing. 
Figure 2: Phosphodiester DNA and a morpholino structures (Corey et al., 2001).  
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However, this progress is hindered by its schedule I classification by the United States 
federal government. Cannabis is not recognized as an accepted form of medical 
treatment; therefore, research on its safety and effectiveness as a medical drug is 
restricted (Drug Enforcement Administration, n.d.). More research is necessary for the 
progression of treatment of epilepsy; effective and safe treatments should be more 
accessible to all people. This entails conducting sufficient research on cannabis in order 
to determine its effectiveness, safety, and mechanism of action.  
CBD is a constituent of cannabis. CBD, which is similar in structure to Δ9-
tetrahydrocannibinol, (THC) (Figure 3), is the major nonpsychoactive component of 
Cannabis sativa. Over the past few years, increasing public and political pressure has 
supported the legalization of medical marijuana. One of the main reasons for this effort is 
related to the treatment of refractory epilepsy such as DS. CBD possesses 
pharmacological effects which are mediated through G protein coupled receptors, 
cannabinoid type I (CB1) and cannabinoid type II (CB2), which are highly expressed in 
the hippocampus and other parts of the central nervous system (Welty et al., 2014). 
However, CBD has very low affinity at CB1 and CB2 unlike THC. When CB1 receptors 
are activated, they inhibit synaptic transmission through action on voltage-gated calcium 
and potassium channels, which are known to modulate epileptiform and seizure activity 
(Falenski et al., 2009). CBD induces a bidirectional change in intracellular calcium levels 
that depends on cellular excitability. Under normal physiological Ca2+ conditions, CBD 
slightly increases intracellular Ca2+, whereas CBD reduces intracellular Ca2+ under high-
excitability conditions (Rosenberg et al., 2015). CBD shows great promise in the 
treatment of epilepsy. Recently, the first cannabis-based pharmaceutical, Epidiolex, was 
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approved by the FDA. It is the first in a new class of treatments with a new mechanism of 
action against epilepsy. Epidiolex is an oral solution of marijuana plant-derived CBD.  
This study was designed to use zebrafish to screen potential anti-epileptic natural 
products such as TG and CBD. We used AB wildtype fish to test compounds in a 
chemically-induced seizure model. Also, we utilized two scn1Lab null zebrafish models; 
these models were created through morpholino injections or chemical mutagenesis.  
 
1.7 Study Goals 
• Test mistletoe extracts in chemically-induced seizure model to assess 
reduction in seizure-like activity. 
• Perform microinjection of an antisense morpholino directed against the 
scn1Lab gene to produce DS phenotypes. 
• Characterize the phenotypic features of scn1Lab -/- and scn1Lab +/-  
transgenic fish. 
• Determine if CBD and clemizole (expected positive control) will reduce 
seizure-like activity in scn1Lab -/- fish. 
Figure 3: ∆-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) structures 
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2. METHODS AND MATERIALS 
 
 2.1 Zebrafish culture and egg collection 
 AB wild-type zebrafish were purchased from Zebrafish International Resource 
Center (ZFIN, Eugene, OR) and raised and tested under the approved IACUC protocol. 
The DeWitte Lab at The University of Leuven kindly provided the transgenic (scn1Lab+/-
) fish, and they were raised under the approved IACUC protocol as well. The zebrafish 
were kept in the Aquatic Habitats ZF0601 Zebrafish Stand-Alone System (Aquatic 
Habitats, Apopka, FL) with each unit containing ~0.3 L of water per fish. The habitats 
contained zebrafish appropriate water (pH 7.0-7.6, 340 parts per million (ppm) Instant 
Ocean, Cincinnati, OH) in a climate (25-28°C) and light (14 hours of light and 10 hours 
of dark) controlled room. They were fed Gemma Micro 300 (Skretting Nutreco 
Company, Westbrook, ME) two times every day. The fish used for breeding did not have 
any form of disease and were also of a healthy breeding age (4-19 months post 
fertilization). To prepare for egg collection, the fish were transferred to breeding tanks at 
a 1:1 ratio of males to females and were then left overnight to produce fertilized eggs. 
 The following morning, after the lights turned on, the fish were returned to their 
normal holding tanks. The eggs which had fallen through the protective metal grate to the 
bottom of the breeding tank were collected by pouring the water from the breeding tanks 
through a sieve. The breeding tanks were rinsed with water and the water was then 
poured through the sieve; this was repeated three times to ensure that every egg had been 
collected.  
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 Unwanted debris and unfertilized/dead eggs were removed after the eggs were 
transferred to a petri dish; this was done by using a transfer pipette. The water in the petri 
dish was then replaced with zebrafish water (60 ppm Instant Ocean, pH 7.5) and placed 
in an incubator at 28°C for five days. Nonviable eggs were removed daily. 
 
2.2 Chemically-induced seizures 
 At 5 days post fertilization (dpf), healthy larvae were transferred to 96-well plates 
(1 larva per well). The larvae were chosen based on lack of deformities. The water in 
each well was removed and replaced with 150 µL of a dosing solution. TG extracts were 
provided from Dr. Jordan Zjawiony. The zebrafish (n=12/treatment/plate; 2 plates) were 
exposed to: control (0.05% DMSO), 25 µM diazepam (DZP; 7 mg/L), and an extract 
from TG (0.2, 1, and 5 mg/L). The TG extract that was tested was AF.1.11.TG.4. Once 
the dosing was complete, the plates were covered with aluminum foil and placed back in 
the incubator.  
 Following a 24-hour exposure to the dosing solutions (6 dpf), morphological 
changes were noted to determine if TG extracts had any toxic side effects including a 
response to touch, pericardial edema, yolk sac edema, a curved body axis and/or a non-
inflated swim bladder (Dietrich, 2017). If any of these morphologies were observed, then 
that larva was excluded from further data analysis. PTZ (Sigma Aldrich; 50 µL of 20 mM 
pentylenetetrazol) was added to each well, except for the first row which was the control, 
to yield a final concentration of 5 mM PTZ. Following addition of PTZ, behavioral 
analysis was conducted. Viewpoint ZebraBox tracked larval movement for 15 minutes 
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with the lights on at 100% with a threshold of 27 and activity parameters were set: 
inactivity (< 5 mm/sec), small (5-9 mm/sec), and large (>9 mm/sec). 
  
2.3 Morpholino injections  
 Numerous trials with amounts ranging from approximately 10-60 ng of scn1a-
MO were conducted. A translation blocking MO (ATG MO: 5′-
CTGAGCAGCCATATTGACATCCTGC-3′) was used to achieve partial knockdown of 
zebrafish scn1Lab. Standard control MO 
(5′-CCTCTTACCTCAGTTACAATTTATA-3′) was used as a negative control. Phenol 
red (0.5 µL) was added to the morpholino solution to ensure visibility of the injected 
solution. All MOs were designed and synthesized by GeneTools LLC (Philomath, 
Oregon, USA) and injected into one-to-two cell stage embryos. MOs were tagged with 
green fluorescent protein (GFP) to ensure that MOs were incorporated into the injected 
fish. In each trial, there were (n≈24) for each treatment group: non-injected, control MO, 
and scn1Lab MO. Following injection, embryos were placed in petri dishes with 
zebrafish water. Subsequently, the petri dishes were placed in the incubator. 
 
2.3a Survival and fluorescent checks 
Embryos were checked daily for mortality and fluorescence until 4 dpf. Embryos 
expressing green fluorescent protein (GFP) showed that the morpholino had been 
successfully incorporated into the genome of the zebrafish. Non-fluorescing and 
nonviable eggs were removed from the petri dishes. At 4 dpf, the remaining larvae were 
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then transferred to 96 well plates with approximately 300 µL of zebrafish water so that 
the water level filled each well completely to the top.  
 
 
2.3b Higher temperature exposure 
 Following the transfer of larvae to a 96 well plate on 4 dpf, a subset of larvae 
were place in an incubator at 34.0°C for 10 minutes and then returned to the incubator at 
28.0°C. This was done to visualize hyperthermia-induced abnormalities/seizures. 
  
2.4 Viewpoint data collection and analysis  
 In the morpholino assay, larvae were screened on 4, 5, and 6 dpf for 
developmental deformities (lack of touch response, yolk sac edema, pericardial edema, 
lack of swim bladder inflation, and body axis) and then the plate was placed in the 
ViewPoint Zebrabox. The larvae were acclimated for 5 minutes before the recording of 
behavior. The ViewPoint Zebrabox tracked larval movement for 45 minutes with the 
lights on at 100%. The ZebraBox software creates an excel sheet that includes the 
duration each larva spends in the inactive (<5 mm/sec), small (5-9 mm/sec), and large 
(>9 mm/sec) movements over the 45-minute period with intervals of 15 minutes. 
Movement that meets the large activity requirements is indicative of seizure activity and 
was the data which was used to test the morpholino knockdown’s effectiveness. After the 
final recording on 6 dpf, the larvae were euthanized with buffered MS-222 and placed in 
RNAlater and stored at -80.0°C.  
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 The data collected from the ViewPoint ZebraBox was analyzed using GraphPad 
Prism 5.0 (La Jolla, CA). The data sets were checked for normality using a Kolmogorov-
Smirnov test. If the data passed the normality test, then statistically significant differences 
between control and treatment groups were determined using a t-test. All tests used p < 
0.05 for determination of statistical significance. 
 In the chemically-induced seizure assay, the parameters for the ViewPoint 
Zebrabox remained the same as in the morpholino assay. However, behavior was tracked 
on 6 dpf for 15 min.  
In the CBD/clemizole experiment, transgenic scn1Lab mutants were utilized. 
Homozygous scn1Lab-/- larvae showed a darker appearance and sometimes a slight 
curvature of the body. No phenotypic difference between WT scn1Lab+/+ and 
heterozygous scn1Lab+/- mutants was observed (Figure 8). At 3-12 dpf, the zebrafish 
were observed for 15 min for behavioral changes using ViewPoint ZebraBox. Pictures 
were taken for the characterization of physical differences between heterozygous and 
homozygous scn1Lab mutants. Behavioral data at 4, 5, 6, and 7 dpf was utilized for 
analysis purposes.   
 
2.5 Transgenic scn1Lab mutants  
 Zebrafish scn1Lab mutant eggs were provided from the University of Leuven. 
Upon arrival, the bleached eggs (20 egg/bottle; 6 bottles = 120 larvae) were dechorinated 
with forceps. The fish were then transferred to petri dishes with 50% Danieau’s solution 
and 50% system water. The petri dishes were then placed in the incubator at 28.0°C. 
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When the larvae reached 5 dpf, they were transferred to the tank system. Around three 
months of age, the zebrafish were spawned. 
 
 
2.5a Exposure assays 
 Zebrafish larvae from a pool of homozygotes, heterozygotes, and wild type 
(scn1Lab-/-, scn1Lab+/-, scn1Lab+/+) were separated based on morphological 
characteristics. On 3dpf, the zebrafish (n=6/treatment) were plated in a 96 well plate. 
After plating, the plate was covered in aluminum foil and placed inside the incubator at 
28°C. On 5 dpf, the larvae were exposed to: control (0.05% DMSO), 1.8 mg/L clemizole 
(5 µM), 0.075 mg/L CBD low (0.25 µM) and 0.3 mg/L CBD high (1 µM). Throughout 
the experiment, the water was static and not changed. Behavior was tracked using the 
ViewPoint ZebraBox before and after treatment; large duration data from 6 dpf and 7 dpf 
was utilized for data analysis. The Viewpoint ZebraBox tracked larval movement for 15 
minutes with the lights on at 100% as described in section 2.4. 
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3. RESULTS  
 
3.1 Chemically-induced seizure  
 Results for the mistletoe assay are shown in Figure 4. Diazepam (7 mg/L; 25 µM) 
showed a significant decrease in large activity when compared to the control group 
treated with PTZ (5 mM). Only 0.2 mg/L of AF.1.11.TG.4 showed a significant decrease 
in large movement compared to 5 mM PTZ. 1 and 5 mg/L of the extract failed to 
significantly decrease large movement when compared to 5 mM PTZ.  
 
 
 
 
 
 
 
 
 
 
Figure 4. AF.1.11.TG.4 seizure activity. Zebrafish larval behavior was analyzed using the 
Viewpoint Zebrabox (15 min recording with 100% light) to record duration of large activity 
(>9mm/sec), following a 24-hr exposure to AF.1.11.TG.4, induced by 5 mM PTZ to determine 
if this compound has anticonvulsant properties (n=10-12 per treatment group, Student t-test 
p≤0.05). Asterisks indicate a significant difference compared to 5 mM PTZ group. 
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3.2 Dravet Syndrome induced by morpholino 
Pictures depicting both control-MO and scn1Lab-MO injections are shown 
(Figure 5). In Figure 5A, two embryos were successfully injected with the control-MO. 
In Figure 5B, two different embryos showed a successful scn1Lab-MO injection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5A-B: Images of morpholino injections. Panel A shows the injection 
of a control-MO into two embryos, and panel B shows the injection of a 
scn1Lab-MO. Red arrows indicate morpholino injection site. 
A 
B 
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3.2a Survival and fluorescent checks 
 Fluorescent checks were done starting at 1 dpf through 4 dpf. These checks were 
to ensure that the morpholino was still incorporated into the embryo. Non-injected fish 
were not included in the table because they did not receive a morpholino injection and 
thus did not fluoresce. Table 1 displays percent of successfully injected embryos at 1 dpf.  
 
 Treatment MO # of fish 
injected 
# of fish 
fluorescing 
at 1 dpf 
% 
fluorescent 
at 1 dpf 
10ng MO  
at 28°C 
Control 197 61 31% 
Scn1a 205 99 48% 
10ng MO  
at 34°C 
Control 59 6 10% 
Scn1a 60 8 13% 
30-60ng 
MO at 28°C 
Control 59 20 34% 
Scn1a 89 26 29% 
Table 1: Percent fluorescing embryos following morpholino injections for normal 
conditions (10 ng MO at 28°C), higher temperature (10 ng MO at 34°C), and 
increased MO amounts at 28°C. Trials under normal conditions (n=60-90/treatment 
group; 3 trials included in data set), higher temperatures and increased MO amounts 
(n=60/treatment group; 1 trial included in data set) were performed. 
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Survival checks were done by calculating percent survival at 4 dpf. Calculations 
were determined by taking the number of living fish on 4 dpf and dividing by the total 
number of fish in that group at 0 dpf. Data under normal conditions (28°C), increased 
temperature conditions (34°C for 10 min), and increased amounts of morpholino is 
depicted in Figure 6.  
 
 
 
 
 
 
 
Figure 6: Percent survival following morpholino injection for normal conditions 
(A), higher temperature (B), and increased morpholino amounts (C). Percent 
survival taken on 4 dpf. Trials under normal conditions (n=60-90/treatment group; 3 
trials included in data set), higher temperature and increased MO amounts 
(n=60/treatment group; 1 trial included in data set) were performed. 
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3.2b ViewPoint data and analysis  
 The results for three trials of morpholino injections under normal conditions are 
shown in Figure 7A. scn1Lab-MO (10 ng) did not increase large movement compared to 
the non-injected treatment group. The results for higher temperature are shown in Figure 
7B. Exposing the fish to a heat of 34°C failed to increase large movement in the scn1Lab-
MO injected group. Figure 7C shows results for zebrafish that were injected with high 
amounts of both control and scn1Lab morpholino. Increased amounts of morpholino did 
not significantly increase large movement compared to the non-injected group.  
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Figure 7: Seizure activity following morpholino injection for normal conditions (a), higher 
temperature (b), and increased morpholino amounts (c). Zebrafish larval behavior was 
analyzed using the ViewPoint Zebrabox (45 min recording with 100% light) to record duration of 
large activity (>9mm/sec) on 4 dpf, 5 dpf, and 6 dpf.  
		 23 
	
3.3 scn1Lab mutant zebrafish 
Transgenic fish were spawned a total of three times and the number of 
homozygous scn1Lab -/- fish were noted in Table 2. Eggs were collected at 0 dpf and 
determination between WT/heterozygous and homozygous took place at 4 dpf. The 
percent of scn1Lab -/- fish was calculated by taking the number of scn1Lab -/- fish and 
dividing that number by the total number of eggs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
# of adult scn1Lab+/- 
spawned 
Total # of 
eggs 
# of scn1a-/- % scn1a-/- 
22 110 24 22% 
12 50 11 22% 
15 60 8 13% 
Sum 220 43 20% 
Table 2: Percentage of homozygotes produced from scn1Lab +/-  mating. Adult 
scn1Lab +/- were spawned three separate times. scn1Lab -/- were identified by 
hyperpigmentation and curved body axes.  
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Figure 8 shows the phenotypic differences between scn1Lab heterozygous and 
homozygous fish. The scn1Lab -/- shows darker pigmentation towards the head region 
and along the edges of the body as well as a lack of a swim bladder.  
 
 
 
 
 
 
 
 
 
Figure 8: Heterozygous and homozygous scn1Lab mutant morphology. A) Example 
of a heterozygous mutant. B) Example of a homozygous mutant.   
Het +/- or WT +/+ 
scn1Lab -/- 
A 
B 
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 Figure 9 demonstrates the difference in large activity duration between 
homozygous (-/-) and heterozygous (+/-) scn1Lab mutants. The percentage of large 
activity duration of scn1Lab +/- to scn1Lab -/- (heterozygous/homozygous) was calculated 
fat 4, 5, 6, and 7 dpf. 4 and 6 showed the largest difference between the heterozygotes 
and the homozygotes at 63% and 66%, respectively. At 5 and 7 dpf the percent difference 
was 45% and 40%, respectively.  
 
 
 
 
 
 
 
 
 
 
Figure 9: Comparison of large activity duration between homozygous (scn1Lab -/-) and 
heterozygous (scn1Lab +/-) mutant zebrafish. Large activity duration was measured in a 
ViewPoint Zebrabox (15 min recording with 100% light) at 4, 5, 6 and 7 dpf. (n=24 on 4 and 5 
dpf; n=6 on 6 and 7 dpf).  
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The results of two different concentrations of CBD is shown in Figure 10. At 24 
hours post treatment (hpf), there was a slight decrease in large activity duration between 
control -/- and clemizole -/-. However, neither of the concentrations of CBD (0.075 and 
0.3 mg/L) showed a significant decrease in the duration of large activity when compared 
to control -/-. While not significant, CBD did show a reduction close to that of clemizole. 
Also, CBD and clemizole treatment reduced -/- activity to that of control +/-. On 7dpf, 
the clemizole -/- treatment group showed an increase in activity. Neither of the 
concentrations of CBD showed a significant decrease in the duration of large activity on 
7dpf.  
 
 
 
 
24 hpRx 
(6dpf) 
48 hpRx (7dpf) 
Figure 10: Seizure activity following clemizole and CBD exposure in 
scn1Lab mutant zebrafish. Scn1Lab mutants that were homozygous (-/-) 
and heterozygous (+/-) were in a ViewPoint ZebraBox (15 min recording 
with 100% light). The duration of large activity following a 24 and 48 
exposure to CBD and clemizole was analyzed to determine if CBD shows 
promise in reducing seizure-like activity (n=6) 
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4. DISCUSSION 
  
The goal of this study was to utilize a scn1Lab deficient zebrafish model to screen 
for potential anti-epileptic natural products. Dravet Syndrome is a highly AED resistant 
form of epilepsy, thus, a screen for compounds or extracts that may show effectiveness 
against seizure activity is necessary. Two natural products were of great interest in this 
research project – CBD and mistletoe. Previous research in our laboratory demonstrated 
that the mistletoe compound, AF.1.11.TG.4, showed promising anti-convulsant results. 
Previous research in our laboratory also showed that CBD is not useful in generalized 
epilepsy; generalized epilepsy trials were conducted using PTZ to induce seizures that 
represent a general form of epilepsy. However, it is important to note that while one drug 
may not work for one form of epilepsy it may work for another. In this case, we 
hypothesized that CBD may show anticonvulsant properties in a scn1Lab deficient 
zebrafish model.  
Tapinathus globiferus, TG, extracts were used in generalized epilepsy assays. The 
most promising extract was AF.1.11.TG.4. Four trials were conducted using the same 
concentrations of extract – 0.2, 1, and 5 mg/L. Success of the assay was based on the 
positive control, diazepam, significantly decreasing PTZ-induced seizure activity. The 
TG extract was run in multiple trials and in only one of the four trials was the duration of 
large activity decreased. Because AF.1.11.TG.4 was not toxic at the highest concentration 
tested and chemically-induced seizure activity was not reduced completely to control 
levels, higher concentrations of this extract can be tested for determination of more 
effective concentrations. Additionally, longer term exposures should be conducted to 
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determine if acute or chronic exposures cause toxicities (Dietrich, 2017). It is important 
to note that CBD was also unsuccessful in treating generalized epilepsy. However, 
previous research conducted by Devinsky et al. (2017) indicated that CBD may show 
promise in reducing seizure-like activity in human DS patients. Thus, TG could 
potentially be useful in treating drug-resistant forms of epilepsy, so further 
experimentation utilizing DS models should be done.  
 A knockdown scn1Lab model in zebrafish was created through the use of an 
antisense oligonucleotide morpholino. Various concentrations ranging from 
approximately 10-60ng of the scn1Lab-MO and exposure to higher temperatures did not 
increase movement in the MO-injected zebrafish either. Fish were exposed to higher 
temperatures to visualize hyperthermia-induced abnormalities because fevers are known 
causes of seizures. Some of the MO-injected zebrafish did possess the desired 
phenotypes- hyperpigmentation, curved body axis, and non-inflated swim bladders. 
These phenotypes are characteristic features of scn1Lab mutant zebrafish as noted in 
previous research (Sourbron et al., 2016; Zhang et al., 2015). Digital imaging of the 
morpholino injection told us that the MO was successfully injected into the embryo. After 
injection, fluorescent screens also proved that the morpholino was still in the embryo. 
However, the knockdown was deemed unsuccessful because behavioral experiments 
using ViewPoint data demonstrated that the MO-injected zebrafish did not show an 
increase in the duration of large activity when compared to the non-injected fish. 
Typically, inhibition of translation is measured through the use of a western blot. 
However, there is no available antibody to this protein in zebrafish. 
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 In research conducted by Zhang et al. (2015), automated video-based behavioral 
tracking system was used to simultaneously monitor and quantify the locomotor activity 
of freely swimming scn1Lab morphants. The scn1Lab morphants displayed 
spontaneously increased total movement as compared to control larvae from 3 to 7 dpf. 
The increase in total movement was initially observed at 3 dpf and became more 
pronounced at 4 and 5 dpf. Movement was extremely minimal on 4 dpf, high in 5 dpf, 
and slightly lower than 5 dpf at 6 dpf. However, in our experiments, the scn1Lab group 
did not show an increase in movement. The control-MO and non-injected groups should 
have demonstrated similar duration in large activity, but they did not. This indicates 
possible adverse effects from the morpholino or injection procedure itself. Also, in our 
results, we did not see larval sensitivity to hyperthermia as seen in Zhang et al. (2015) 
results.  
Zhang et al. (2015) also performed higher-resolution video recording to capture 
more subtle larval seizure behaviors not detected by the automated tracker. They found 
that scn1Lab morphant larvae displayed not only increased total movement in scn1Lab 
morphants but also abnormal behavior. Larvae displayed jerking behavior and sudden 
stiffening and relaxation of the entire body. Higher-resolution video recording was not 
done in our experiments. If further experimentation were to be done, this could be a 
viable option for tracking behavior.  
 Because the scn1Lab knockdown model was unsuccessful, chemically mutated 
transgenic fish were utilized. Fish with the scn1Lab gene knocked out were used in the 
CBD assay. We hypothesized that CBD would be an effective anti-convulsant compound 
against DS due to previous research (Cunha et al., 1980; Devinsky et al., 2017). 
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Experimental results obtained from ViewPoint data demonstrated that both 0.075 mg/L 
CBD (0.25 µM) and 0.3 mg/L CBD (1 µM) did not significantly decrease the duration of 
large activity. In the homozygous group, clemizole decreased large activity duration on 6 
dpf, but lost its efficacy on 7 dpf. This experiment was only conducted once with 6 
homozygous and 6 heterozygous/wildtype per treatment group. Also, the activity of the 
CBD groups and clemizole groups are extremely close in 6 dpf. Therefore, further 
experimentation is necessary to determine whether or not CBD is an effective anti-
epileptic drug for DS. In addition, various concentrations of CBD need to be tested. 
Increasing the amount of time for the behavioral experiments from 15 min to 45 min will 
increase the potential to observe seizure-like activity in each treatment group. In our 
experiment, we used 6 fish per treatment. Thus, increasing the number of fish in each 
treatment group could increase significance as well. Because both concentrations of CBD 
seemed to lose efficacy at 7 dpf, daily dosing may be necessary in later experiments. 
 Clemizole 1.8 mg/L (5µM) was used as a positive control in the CBD/clemizole 
assay with scn1Lab fish. Clemizole was used based on previous research conducted by 
Baraban et al. (2013). Their group found that clemizole was effective in suppressing 
spontaneous seizure activity in their mutant DS lines. Although clemizole did not 
significantly decrease large activity movement in our experiment, there was some 
decrease in large movement as compared to the control group. Clemizole seemed to lose 
its efficacy on 7 dpf in the homozygous group; this could be due to natural metabolism of 
the drug. Clemizole also showed toxic effects in the heterozygous group on 7 dpf. 
Another promising anti-epileptic drug, fenfluramine, has been found to significantly 
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reduce epileptiform discharges in scn1Lab morphants (Zhang et al., 2015). Thus, 
fenfluramine could be used in future experimentation as a comparison to CBD.  
Although CBD failed to significantly decrease large activity movement in our 
experiment, Cunha et al. (1980) found that CBD administration inhibited the effect of 
PTZ in rats, decreased the astrocytic hyperplasia, decreased neuronal damage in the 
hippocampus caused by the seizures and selectively reduced the expression of the NR1 
subunit of NMDA (Cunha et al., 2015). Because CBD shows potential in larger animal 
models, this assay may show successful results in human studies. Multiple small studies 
of CBD safety in humans in both placebo-controlled and open trials have demonstrated 
that it is well tolerated across a wide dosage range. No significant central nervous system 
side effects, or effects on vital signs or mood have been seen at doses up to 1,500 mg/day 
(p.o.) or 30 mg (i.v.) in both acute and chronic administration (Devinsky et al., 2014). 
Thus, CBD is still a viable option in treating drug-resistant forms of epilepsy, so further 
experimentation utilizing DS models should be done.  
In conclusion, three different anti-epilepsy in vivo drugs screens were used in this 
research project. PTZ-induced screens represent a generalized seizure model and are 
relatively easy to conduct using diazepam as a positive control. In this screen, TG failed 
to decrease PTZ-induced activity. However, this result does not necessarily suggest that 
extracts will not be effective in DS epilepsy. Therefore, we targeted scn1Lab 
knockdown/out for a syndrome specific screening. Despite multiple manipulations, the 
morpholino-based approach did not generate the expected seizure phenotypes. Thus, the 
transgenic scn1Lab fish were a far better model for routine screening. Initial results for 
both the positive control clemizole and CBD suggest the assay is working as expected 
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and that CBD inhibits scn1Lab –mediated seizures. Further work with higher sample 
sizes and more concentrations will be needed to confirm these initial promising results.  
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